Brief: Gen Ilac Says It Signs Distribution Agreement With Santhera Pharmaceuticals, Based In Switzerland
13/08/2025 08:06
Aug 13 (Reuters) - GEN İLAÇ VE SAĞLIK ÜRÜNLERİ SANAYİ VE TİCARET GENIL.IS: GEN ILAÇ AND SANTHERA PHARMACEUTICALS, BASED IN SWITZERLAND, SIGNS AN EXCLUSIVE DISTRIBUTION AGREEMENT UNDER THE AGREEMENT, GEN WILL BE THE EXCLUSIVE DISTRIBUTOR IN TÜRKIYE FOR AGAMREE® (VAMOROLONE), A PRODUCT USED IN THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS AGED FOUR YEARS AND OLDER SUPPLY AND SALES OF THE DRUG ARE EXPECTED TO BEGIN IN THE FIRST HALF OF 2026 UPON THE AGREEMENT COMING INTO EFFECT, GEN WILL FOLLOW THE NECESSARY PROCEDURES FOR THE DRUG TO BE ADDED TO THE FOREIGN DRUG LIST OF THE TURKISH MINISTRY OF HEALTH, AND ONCE THE PROCESS IS COMPLETE, THE DRUG WILL BE SUPPLIED AND SOLD IN TÜRKIYE UNDER THE NAMED PATIENT PROGRAM (NPP) Source text for Workspace: nIKA9sKByX Further company coverage: GENIL.IS (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Gen Ilac ve Saglik Urunleri Sanayi Ticaret
See all newsBrief: Gen Ilac Says It Wins Pharmaceutical Tender In Kazakhstan, Expects $1.19 Million Sales Contribution In 2027
Brief: Gen Ilac Says It Participates In Kazakhstan Drug Procurement Tender Via Med Service Plus Authorized By Kazakhstan Representative Office Of Gen Ilac
Brief: Gen Ilac Says It Signs Supply And Distribution Agreement With Incyte On Oct 9
Brief: Gen Ilac Says It Completes Pharmaceutical Manufacturing Plant Investment In Azerbaijan
Brief: Gen Ilac Says It Is To Start Share Buyback Programme For Max 125 Mln Nominal Shares With Allocated Funds Of 1.5 Bln Lira